Floatz Rating
BB69/100
Confidence
Indicative
Sponsor
Sichuan Baili Pharmaceutical Co., Ltd.
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
67High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07545460CT.gov A Study Comparing BL-M07D1 With Physician's Choice of Chemotherapy in Patients With HER2-Expressing Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer | — | Not Yet Recruiting | — | — | — |
NCT07218809CT.gov AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer | — | Recruiting | — | — | — |
NCT06994195CT.gov A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer(PANKU-GYN01) | — | Recruiting | — | — | — |
NCT05870748CT.gov REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1 | — | Terminated | — | — | — |
NCT05483933CT.gov Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers | — | Completed | — | — | — |
NCT05261490CT.gov Study of Maplirpacept (PF-07901801) in Combination With PLD in Patients With Platinum-Resistant Ovarian Cancer | — | Terminated | — | — | — |
NCT05295589CT.gov Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor Therapy | — | Withdrawn | — | — | — |
NCT05271318CT.gov Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment for Ovarian Cancer. | — | Active Not Recruiting | — | — | — |
NCT04983550CT.gov Efficacy and Safety of SG001 Combined With PLD in Patients With Platinum-resistant Relapsed EOC | — | Unknown | — | — | — |
NCT04811703CT.gov Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Associated With Systemic Chemotherapy in Women With Advanced Ovarian Cancer | — | Recruiting | — | — | — |
Show 44 more trialsShow fewer
NCT04739800CT.gov Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents | — | Active Not Recruiting | — | — | — |
NCT04516447CT.gov A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer | — | Recruiting | — | — | — |
NCT04092270CT.gov A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer | — | Active Not Recruiting | — | — | — |
NCT04244552CT.gov A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies | — | Terminated | — | — | — |
NCT04209855CT.gov A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression | — | Completed | — | — | — |
NCT04213794CT.gov Heated Intra-peritoneal Chemotherapy With Doxorubicin and Cisplatin for Abdominal for Pelvic Tumors in Pediatric Patients | — | Terminated | — | — | — |
NCT03690739CT.gov Evaluation of Symptom Benefit Rate of Trabectedin/PLD in Patients With Recurrent Ovarian Cancer | — | Terminated | — | — | — |
NCT03872947CT.gov A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT03598270CT.gov Platinum-based Chemotherapy With Atezolizumab and Niraparib in Patients With Recurrent Ovarian Cancer | — | Completed | — | — | — |
NCT03542669CT.gov Study of 6b11-OCIK Injection Treatment in Patients With Recurrent Drug-resistant Ovarian Cancer | — | Unknown | — | — | — |
NCT03562533CT.gov Real-World Effectiveness of PLD in Platinum- Sensitive Recurrent Ovarian Cancer | — | Completed | — | — | — |
NCT03509246CT.gov Bortezomib and Pegylated Liposomal Doxorubicin in BRCA Wild-type Platinum-resistant Recurrent Ovarian Cancer Patients | — | Unknown | — | — | — |
NCT02839707CT.gov Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | — | Active Not Recruiting | — | — | — |
NCT02822157CT.gov Circulating Tumor DNA Guiding (Olaparib) Lynparza® Treatment in Ovarian Cancer | — | Unknown | — | — | — |
NCT02502266CT.gov Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer | — | Active Not Recruiting | — | — | — |
NCT02446600CT.gov Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | — | Active Not Recruiting | — | — | — |
NCT02631876CT.gov A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer | — | Completed | — | — | — |
NCT02606305CT.gov Study of Mirvetuximab Soravtansine in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin in Participants With Folate Receptor Alpha (FRα) Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal, or Fallopian Tube Cancer | — | Completed | — | — | — |
NCT02584478CT.gov Phase 1/2a/3 Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002) | — | Unknown | — | — | — |
NCT02312245CT.gov Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | — | Completed | — | — | — |
NCT02419495CT.gov Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies | — | Terminated | — | — | — |
NCT02489903CT.gov RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT) | — | Completed | — | — | — |
NCT02364713CT.gov MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer | — | Terminated | — | — | — |
NCT02260544CT.gov Bioequivalence Study of Doxorubicin Hydrochloride Liposome Injection | — | Completed | — | — | — |
NCT01970722CT.gov Surgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopian Tube, Uterine, or Peritoneal Cancer | — | Active Not Recruiting | — | — | — |
NCT02107378CT.gov Efficacy of DCVAC/OvCa Plus Standard of Care in Relapsed Platinum Resistant Epithelial Ovarian Carcinoma | — | Terminated | — | — | — |
NCT01840943CT.gov A Study to Compare CAELYX With Topotecan HCL in Patients With Recurrent Epithelial Ovarian Carcinoma Following Failure of First-Line, Platinum-Based Chemotherapy | — | Terminated | — | — | — |
NCT02394015CT.gov Retrospective Study to Analyze the Efficacy and Safety of Trabectedin and Pegylated Liposomal Doxorubicin (PLD ) in the Treatment of Patients With Platinum-sensitive Recurrent Ovarian Cancer (ROC), According to SmPC | — | Completed | — | — | — |
NCT01666444CT.gov VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer | — | Completed | — | — | — |
NCT01715168CT.gov A Crossover Bioequivalence Study of Intravenously Administered ATI0918 and DOXIL/CAELYX in Patients With Ovarian Cancer | — | Unknown | — | — | — |
NCT01489371CT.gov EGEN-001 and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | — | Completed | — | — | — |
NCT01459380CT.gov Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer | — | Completed | — | — | — |
NCT01294293CT.gov TLR8 Agonist VTX-2337 and Pegylated Liposomal Doxorubicin Hydrochloride or Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer | — | Completed | — | — | — |
NCT01281514CT.gov A Study of Carboplatin, PLD and Everolimus in Certain Gynecologic Cancer | — | Completed | — | — | — |
NCT01202890CT.gov Study of Revlimid With Doxil and Avastin for Patients With Platinum Resistant Ovarian Cancer | — | Terminated | — | — | — |
NCT01145430CT.gov Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer | — | Completed | — | — | — |
NCT01091428CT.gov Alisertib (MLN8237) in Participants With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast Cancer | — | Completed | — | — | — |
NCT01004380CT.gov Safety Study of Farletuzumab, Carboplatin and Pegylated Liposomal Doxorubicin (PLD) to Treat Platinum-sensitive Ovarian Cancer | — | Completed | — | — | — |
NCT00861120CT.gov Panitumumab and Pegylated Liposomal Doxorubicin for Platinum-Resistant Epithelial Ovarian Cancer With KRAS Wild-type | — | Completed | — | — | — |
NCT01673217CT.gov Decitabine, Vaccine Therapy, and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer | — | Completed | — | — | — |
NCT00853307CT.gov MLN8237 for Treatment of Participants With Ovarian, Fallopian Tube, or Peritoneal Carcinoma | — | Completed | — | — | — |
NCT00880360CT.gov A Trial of Intravenous Denileukin Diftitox in Stage III or IV Ovarian Cancer | — | Completed | — | — | — |
NCT00312650CT.gov Doxil and Gemcitabine in Recurrent Ovarian Cancer | — | Terminated | — | — | — |
NCT00182767CT.gov Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Ovarian Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Adriamycin (this asset) | Sichuan Baili Pharmaceutical Co., Ltd. | P3 | BB · 69 |
| Mirvetuximab Soravtansine | AstraZeneca | P3 | BBB |
| Trabectedin | AGO Research GmbH | P4 | BBB |
| Carboplatin | University of Washington | P3 | BB |
| Olaparib | Imunon | P4 | BB |
| Irinotecan | OHSU Knight Cancer Institute | P2 | BB |
| Durvalumab | AGO Research GmbH | P2 | BB |
| Lenvatinib | University Medical Center Groningen | P4 | BB |
| Palbociclib | University Medical Center Groningen | P4 | BB |
+42 more in the Ovarian Carcinoma cohort
Other indications for Adriamycin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Adult Acute Lymphoblastic Leukemia | — | P4 | BBB · 77 |
| B-Cell Childhood Acute Lymphoblastic Leukemia | — | P3 | BBB · 76 |
| Hematopoietic And Lymphoid System Neoplasm | — | P4 | BBB · 76 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Adriamycin in Ovarian Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/adriamycin-ovarian-carcinoma-49867
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →